Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10124071-B2

Patent

Publication Date

2018-11-13

Expiration Date


Abstract

The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.

Core Innovation

The invention concerns solubilizing poorly soluble ST-246 in a liquid formulation containing cyclodextrin and pharmaceutically acceptable ingredients. Hydroxypropyl-β-cyclodextrin (HP-β-CD) is identified as a preferred cyclodextrin, and the formulation accommodates ST-246 Forms I–VI. The formulation contains a therapeutically effective amount of ST-246 in a pharmaceutically acceptable liquid carrier.

The problem addressed is the poor solubility of ST-246. The disclosed solubility studies report that ST-246 solubility increases with increasing HP-β-CD concentration and temperature. The independent claim is described as a process for making the liquid formulation, with optional filtration identified and [procedural detail omitted for safety].

Figures 4 to 10 depict cyclodextrin structures and formulation data showing concentration- and condition-dependent ST-246 solubility, including effects of cyclodextrin type and level, temperature, pH, and dilution. The plotted results support cyclodextrin-based liquid formulations. Other figures show monkey pharmacokinetic profiles for intravenous and oral ST-246 dosing and diffraction patterns of ST-246 samples.

Claims Coverage

The provided claims identify one independent claim, claim 1, covering one inventive feature. The claim is described both as a process for making a liquid formulation and as a liquid formulation of the same components.

Liquid formulation containing ST-246 and cyclodextrin

The independent claim covers a liquid formulation, or a process for making it, comprising a therapeutically effective amount of ST-246, cyclodextrin, and one or more pharmaceutically acceptable ingredients in a pharmaceutically acceptable liquid carrier. Optional filtration is also identified in the claim. [procedural detail omitted for safety].

The independent claim focuses on a liquid formulation containing ST-246 and cyclodextrin in a pharmaceutically acceptable liquid carrier, and on a process for making it.

Stated Advantages

The disclosed formulation addresses the poor solubility of ST-246; the solubility studies report increasing ST-246 solubility with increasing HP-β-CD concentration and temperature.

Documented Applications

A liquid formulation comprising a therapeutically effective amount of ST-246, cyclodextrin, and pharmaceutically acceptable ingredients.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.